briakinumab   Click here for help

GtoPdb Ligand ID: 9213

Synonyms: ABT-874 | J-695 | J695 | Ozespa
Immunopharmacology Ligand
Compound class: Antibody
Comment: Briakinumab is a recombinant, fully human, IgG1 investigational monoclonal antibody targeting the shared p40 subunit of IL-12 and IL-23. Peptide sequences matching those of briakinumab are claimed in patent US6914128 'Human antibodies that bind human IL-12 and methods for producing' [2].
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: pericyazine

1. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J, ABT-874 Psoriasis Study Investigators. (2008)
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
Arch Dermatol, 144 (2): 200-7. [PMID:18283176]
2. Salfeld J, Roguska M, Paskind M, Banerjee S, Tracey D, White M, Kaymakcalan Z, Labkovsky B, Sakorafas P, Veldman GM. (2005)
Human antibodies that bind human IL-12 and methods for producing.
Patent number: US6914128. Assignee: Abbott Gmbh & Co. Kg. Priority date: 25/03/1999. Publication date: 05/07/2005.